Grail raises $300 million in Series C round to give massive boost to the development of its liquid biopsy applications for cancer.
A new study shows proposed changes in the International Classification of Diseases (ICD) guidelines could lead to a reduction in the diagnosis of PTSD patients.
Myriad Genetics presented results from a 24-week study that showed Major Depressive Disorder patients were 50% more likely to achieve remission and 30% more likely to respond to treatment using the GeneSight Psychotropic genetic test.
Orion Diagnostica develops Point-of-Care tests and earned about $67 million in sales for its most recent reported year.
Bristol-Myers Squibb has teamed up with Illumina to develop companion diagnostics for oncology immunotherapies.
Qiagen has developed liquid biopsy panels for prostate and lung cancer and is set to introduce the products at the American Association for Cancer Research annual meeting this week.
These seven medtech companies aren't just moving the needle, they're getting rid of it all together!
A new study has confirmed the accuracy of the Xpresys Lung 2 test developed by Integrated Diagnostics.
Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.
SQI Diagnostics and Predictive Health bring cardiovascular diagnostics to the forefront with the launch of a serum-based heart attack probability test.
The company says its ImmunoPoC platform can determine in 15 minutes whether a patient has a bacterial or viral infection.
A $45 million funding round completed by DiaCarta to help develop a liquid biopsy test for colorectal cancer is just the latest proof that venture capitalists continue to see liquid biopsy companies as an attractive investment.